H4 Orphan is pleased to announce a strategic agreement between TheraVet and H4 Orphan Pharma whereby H4 Orphan Pharma’s lead clinical programme in idiopathic pulmonary fibrosis is contributed to TheraVet in exchange for the issue of new shares.
On completion of this transaction, H4 Orphan Pharma will own more than 95% of the new entity. The company will be listed on Euronext Brussels.
The aim of this transaction is to accelerate H4 Orphan Pharma’s flagship programme in pulmonary fibrosis, with the launch of its phase 2 trial, and to leverage the complementary expertise and resources of the two companies.
H4 Orphan Pharma is providing TheraVet with a pharmaceutical active ingredient, tritoqualine, for the treatment of idiopathic pulmonary fibrosis (IPF), currently in early clinical phase.
Tritoqualine was granted full Scientific and Technical Advice (Full STA) by the FAMHP (Belgian Medicines Agency) in December 2023, with a favourable opinion to go directly in phase 2 for IPF.
Alongside this contribution, H4 Orphan Pharma has granted a licence on its 18 patents validated worldwide, mainly in the USA, China and Europe.
Tritoqualine is a pharmaceutical molecule known for its safety and multi-targeted pharmacological activity (multifunctional ligand).
Tritoqualine has produced remarkable results in fibrosis, both in animal models and in humans.
Statement from the CEO of H4 Orphan Pharma:
“Our Board of Directors is convinced that the strategic agreement with TheraVet will boost our development programme in Belgium, and fully supports this operation. TheraVet team will be able to lead and accelerate the clinical development plan in pulmonary fibrosis with a phase 2 study designed to validate the clinical evidence for our treatment, enabling a breakthrough innovation in an area with no truly effective treatment. Together with our management team, we look forward to working with TheraVet”, says Doctor Gaëtan Terrasse, CEO of H4 Orphan Pharma.